UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 9, 2003
Targeted Genetics Corporation
| Washington | 0-23930 | 91-1549568 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
||
| 1100 Olive Way, Suite 100, Seattle, Washington |
98101 |
|||
| (Address of principal executive offices) |
|
(Zip Code) |
||
Registrant’s telephone number, including area code (206) 623-7612
Not Applicable
| Item 5. Other Events. | ||||||||
| Item 7. Exhibits. | ||||||||
| SIGNATURES | ||||||||
| EXHIBIT INDEX | ||||||||
| EXHIBIT 99.1 | ||||||||
Item 5. Other Events.
On December 9, 2003, Targeted Genetics Corporation issued a press release announcing the initiation of a clinical trial of tgAAV09, its HIV/AIDS vaccine candidate. The text of the press release is set forth in Exhibit 99.1 attached to this release and incorporated herein by this reference.
Item 7. Exhibits.
| (a) | Financial statements of business acquired. |
| Not applicable. |
| (b) | Pro forma financial information. |
| Not applicable. |
| (c) | Exhibits. |
| Exhibit | ||
| No. | Description | |
| 99.1 | Press Release of Targeted Genetics Corporation dated December 9, 2003 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| TARGETED GENETICS CORPORATION | ||||
| By: | /s/ Todd E. Simpson | |||
| Date: December 9, 2003 | Todd E. Simpson | |||
| Vice President, Finance and Administration and Chief Financial Officer, Secretary and Treasurer (Principal Financial and Accounting Officer) | ||||
EXHIBIT INDEX
| Exhibit | ||
| No. | Description | |
| 99.1 | Press Release of Targeted Genetics Corporation dated December 9, 2003 |